IDEXX Begin Period Cash Flow vs Capital Expenditures Analysis

0J8P Stock

432.54 1.63 0.38%

IDEXX Laboratories financial indicator trend analysis is infinitely more than just investigating IDEXX Laboratories recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether IDEXX Laboratories is a good investment. Please check the relationship between IDEXX Laboratories Begin Period Cash Flow and its Capital Expenditures accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.

Begin Period Cash Flow vs Capital Expenditures

Begin Period Cash Flow vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of IDEXX Laboratories Begin Period Cash Flow account and Capital Expenditures. At this time, the significance of the direction appears to have no relationship.

The correlation between IDEXX Laboratories' Begin Period Cash Flow and Capital Expenditures is 0.09. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of IDEXX Laboratories, assuming nothing else is changed. The correlation between historical values of IDEXX Laboratories' Begin Period Cash Flow and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of IDEXX Laboratories are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Begin Period Cash Flow i.e., IDEXX Laboratories' Begin Period Cash Flow and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

0.09

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by IDEXX Laboratories to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of IDEXX Laboratories operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most indicators from IDEXX Laboratories' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into IDEXX Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.Selling General Administrative is likely to drop to about 187 M in 2024. Tax Provision is likely to drop to about 109.4 M in 2024

	2021	2022	2023	2024 (projected)
Total Revenue	3.2B	3.4B	3.7B	3.8B
Depreciation And Amortization	104.6M	111.9M	114.9M	120.7M

Total Revenue Depreciation And Amortization

IDEXX Laboratories fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Non Current Liabilities Total	Intangible Assets	Short Long Term Debt Total	Short Term Debt	Common Stock	Short Term Investments	Current Deferred Revenue
Total Assets		0.95	0.75	0.73	0.99	0.49	0.91	0.95	0.63	0.98	0.76	0.48	0.98	-0.32	0.97	0.47	-0.92	0.82	0.96	0.77	0.68	0.69	0.14	0.54	0.88	0.6
Other Current Liab	0.95		0.71	0.59	0.95	0.57	0.82	0.97	0.46	0.96	0.85	0.33	0.96	-0.41	0.9	0.46	-0.86	0.86	0.87	0.88	0.69	0.71	0.1	0.59	0.87	0.75
Total Current Liabilities	0.75	0.71		0.19	0.72	0.86	0.52	0.77	0.27	0.69	0.43	0.48	0.69	-0.28	0.76	0.78	-0.65	0.92	0.78	0.73	0.55	0.94	0.75	0.67	0.77	0.56
Total Stockholder Equity	0.73	0.59	0.19		0.71	-0.22	0.89	0.59	0.75	0.72	0.6	0.33	0.73	0.05	0.74	-0.01	-0.75	0.2	0.69	0.19	0.57	0.03	-0.37	0.14	0.51	0.09
Property Plant And Equipment Net	0.99	0.95	0.72	0.71		0.49	0.9	0.95	0.59	0.99	0.78	0.41	0.98	-0.37	0.96	0.41	-0.91	0.81	0.93	0.79	0.63	0.68	0.09	0.51	0.88	0.65
Net Debt	0.49	0.57	0.86	-0.22	0.49		0.17	0.61	-0.14	0.47	0.31	0.22	0.48	-0.54	0.48	0.65	-0.35	0.89	0.48	0.79	0.26	0.95	0.74	0.51	0.55	0.64
Retained Earnings	0.91	0.82	0.52	0.89	0.9	0.17		0.84	0.67	0.92	0.76	0.3	0.92	-0.19	0.93	0.27	-0.97	0.55	0.83	0.5	0.72	0.38	-0.08	0.33	0.7	0.42
Accounts Payable	0.95	0.97	0.77	0.59	0.95	0.61	0.84		0.4	0.97	0.82	0.3	0.97	-0.43	0.93	0.46	-0.89	0.86	0.87	0.83	0.71	0.73	0.18	0.53	0.85	0.69
Cash	0.63	0.46	0.27	0.75	0.59	-0.14	0.67	0.4		0.52	0.25	0.76	0.53	0.18	0.56	0.3	-0.55	0.27	0.73	0.23	0.32	0.19	-0.14	0.32	0.55	0.14
Non Current Assets Total	0.98	0.96	0.69	0.72	0.99	0.47	0.92	0.97	0.52		0.84	0.31	1.0	-0.37	0.96	0.39	-0.94	0.79	0.89	0.78	0.71	0.64	0.06	0.5	0.85	0.65
Non Currrent Assets Other	0.76	0.85	0.43	0.6	0.78	0.31	0.76	0.82	0.25	0.84		-0.03	0.84	-0.32	0.75	0.12	-0.77	0.58	0.6	0.64	0.67	0.39	-0.14	0.36	0.66	0.57
Cash And Short Term Investments	0.48	0.33	0.48	0.33	0.41	0.22	0.3	0.3	0.76	0.31	-0.03		0.33	0.08	0.39	0.5	-0.23	0.41	0.7	0.31	0.09	0.47	0.3	0.39	0.5	0.04
Net Receivables	0.98	0.96	0.69	0.73	0.98	0.48	0.92	0.97	0.53	1.0	0.84	0.33		-0.41	0.96	0.37	-0.93	0.8	0.9	0.78	0.68	0.65	0.06	0.47	0.84	0.63
Common Stock Shares Outstanding	-0.32	-0.41	-0.28	0.05	-0.37	-0.54	-0.19	-0.43	0.18	-0.37	-0.32	0.08	-0.41		-0.27	-0.05	0.3	-0.5	-0.22	-0.63	0.11	-0.48	-0.04	0.2	-0.11	-0.55
Inventory	0.97	0.9	0.76	0.74	0.96	0.48	0.93	0.93	0.56	0.96	0.75	0.39	0.96	-0.27		0.46	-0.93	0.77	0.92	0.68	0.75	0.66	0.2	0.5	0.82	0.52
Other Current Assets	0.47	0.46	0.78	-0.01	0.41	0.65	0.27	0.46	0.3	0.39	0.12	0.5	0.37	-0.05	0.46		-0.43	0.69	0.56	0.52	0.56	0.74	0.74	0.76	0.56	0.52
Other Stockholder Equity	-0.92	-0.86	-0.65	-0.75	-0.91	-0.35	-0.97	-0.89	-0.55	-0.94	-0.77	-0.23	-0.93	0.3	-0.93	-0.43		-0.68	-0.82	-0.62	-0.76	-0.53	-0.09	-0.42	-0.74	-0.58
Total Liab	0.82	0.86	0.92	0.2	0.81	0.89	0.55	0.86	0.27	0.79	0.58	0.41	0.8	-0.5	0.77	0.69	-0.68		0.8	0.94	0.5	0.97	0.52	0.65	0.83	0.78
Total Current Assets	0.96	0.87	0.78	0.69	0.93	0.48	0.83	0.87	0.73	0.89	0.6	0.7	0.9	-0.22	0.92	0.56	-0.82	0.8		0.71	0.6	0.72	0.25	0.56	0.86	0.48
Non Current Liabilities Total	0.77	0.88	0.73	0.19	0.79	0.79	0.5	0.83	0.23	0.78	0.64	0.31	0.78	-0.63	0.68	0.52	-0.62	0.94	0.71		0.39	0.86	0.26	0.55	0.77	0.87
Intangible Assets	0.68	0.69	0.55	0.57	0.63	0.26	0.72	0.71	0.32	0.71	0.67	0.09	0.68	0.11	0.75	0.56	-0.76	0.5	0.6	0.39		0.36	0.19	0.64	0.62	0.41
Short Long Term Debt Total	0.69	0.71	0.94	0.03	0.68	0.95	0.38	0.73	0.19	0.64	0.39	0.47	0.65	-0.48	0.66	0.74	-0.53	0.97	0.72	0.86	0.36		0.69	0.61	0.73	0.68
Short Term Debt	0.14	0.1	0.75	-0.37	0.09	0.74	-0.08	0.18	-0.14	0.06	-0.14	0.3	0.06	-0.04	0.2	0.74	-0.09	0.52	0.25	0.26	0.19	0.69		0.48	0.28	0.19
Common Stock	0.54	0.59	0.67	0.14	0.51	0.51	0.33	0.53	0.32	0.5	0.36	0.39	0.47	0.2	0.5	0.76	-0.42	0.65	0.56	0.55	0.64	0.61	0.48		0.8	0.61
Short Term Investments	0.88	0.87	0.77	0.51	0.88	0.55	0.7	0.85	0.55	0.85	0.66	0.5	0.84	-0.11	0.82	0.56	-0.74	0.83	0.86	0.77	0.62	0.73	0.28	0.8		0.68
Current Deferred Revenue	0.6	0.75	0.56	0.09	0.65	0.64	0.42	0.69	0.14	0.65	0.57	0.04	0.63	-0.55	0.52	0.52	-0.58	0.78	0.48	0.87	0.41	0.68	0.19	0.61	0.68

Click cells to compare fundamentals

IDEXX Laboratories Account Relationship Matchups

IDEXX Laboratories fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.8B	2.3B	2.4B	2.7B	3.3B	3.4B
Other Current Liab	276.5M	355.2M	396.4M	364.7M	372.4M	391.0M
Total Current Liabilities	725.3M	582.8M	763.6M	1.2B	951.5M	999.1M
Total Stockholder Equity	177.5M	632.1M	690.0M	608.7M	1.5B	1.6B
Property Plant And Equipment Net	533.8M	555.2M	587.7M	649.5M	817.7M	858.6M
Net Debt	897.3M	524.6M	779.2M	1.2B	613.4M	644.1M
Retained Earnings	1.6B	2.2B	2.9B	3.6B	4.4B	4.7B
Accounts Payable	72.2M	74.6M	116.1M	110.2M	110.6M	116.2M
Cash	90.3M	383.9M	144.5M	112.5M	453.9M	476.6M
Non Current Assets Total	1.2B	1.2B	1.5B	1.6B	1.8B	1.9B
Non Currrent Assets Other	299.0M	337.2M	397.4M	425.6M	333.0M	349.6M
Cash And Short Term Investments	90.3M	383.9M	144.5M	112.5M	453.9M	476.6M
Net Receivables	307.5M	374.7M	425.6M	490.9M	529.5M	556.0M
Common Stock Shares Outstanding	87.5M	86.7M	86.6M	84.6M	84.0M	94.9M
Liabilities And Stockholders Equity	1.8B	2.3B	2.4B	2.7B	3.3B	3.4B
Inventory	195.0M	209.9M	269.0M	367.8M	380.3M	399.3M
Other Current Assets	86.8M	94.2M	116.6M	130.2M	131.5M	75.1M
Other Stockholder Equity	(1.4B)	(1.5B)	(2.2B)	(2.9B)	(2.9B)	(2.8B)
Total Liab	1.7B	1.7B	1.7B	2.1B	1.8B	1.9B
Total Current Assets	679.6M	1.1B	955.7M	1.1B	1.5B	1.6B
Non Current Liabilities Total	929.3M	1.1B	983.6M	902.2M	823.8M	865.0M
Intangible Assets	58.5M	52.5M	99.0M	97.7M	84.5M	66.7M
Short Long Term Debt Total	987.7M	908.5M	923.7M	1.3B	1.1B	1.1B
Short Term Debt	304.0M	67.7M	168.4M	674.4M	344.8M	212.2M
Accumulated Other Comprehensive Income	(46.2M)	(53.6M)	(53.5M)	(77.8M)	(71.2M)	(67.6M)
Common Stock	10.6M	10.6M	10.7M	10.7M	10.8M	9.2M
Current Deferred Revenue	41.5M	42.6M	40.0M	37.9M	37.2M	25.0M
Good Will	239.7M	243.3M	359.3M	361.8M	366.0M	218.6M
Other Assets	240.2M	289.6M	325.2M	1.0	1.15	1.09
Other Liab	162.9M	143.5M	121.0M	106.6M	95.9M	115.4M
Net Tangible Assets	(120.7M)	336.2M	231.6M	149.3M	171.7M	180.2M
Long Term Debt	499.6M	599.5M	858.5M	775.2M	891.5M	711.1M
Deferred Long Term Liab	108.6M	116.1M	122.4M	119.9M	137.9M	115.7M
Property Plant Equipment	614.5M	646.3M	692.8M	768.1M	883.3M	648.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for IDEXX Stock Analysis

When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

IDEXX Begin Period Cash Flow vs Capital Expenditures Analysis

Begin Period Cash Flow vs Capital Expenditures

Begin Period Cash Flow vs Capital Expenditures Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Capital Expenditures

IDEXX Laboratories fundamental ratios Correlations

IDEXX Laboratories Account Relationship Matchups

High Positive Relationship

High Negative Relationship

IDEXX Laboratories fundamental ratios Accounts

Also Currently Popular

Additional Tools for IDEXX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Receivables	+ 1.0	Non Current Assets Total
Property Plant And Equipment Net	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Non Current Assets Total	+ 0.98	Total Assets
Net Receivables	+ 0.98	Total Assets
Net Receivables	+ 0.98	Property Plant And Equipment Net

Other Stockholder Equity	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.94	Non Current Assets Total
Other Stockholder Equity	- 0.93	Inventory
Other Stockholder Equity	- 0.93	Net Receivables
Other Stockholder Equity	- 0.92	Total Assets
Other Stockholder Equity	- 0.91	Property Plant And Equipment Net